RPHM היקף נכסי החברה Reneo Pharma

This market valuation chart for Reneo Pharmaceuticals (RPHM) on the GURU.Markets platform demonstrates total assets, which currently stand at 113.37. The business generates revenue by bringing treatments for mitochondrial pathologies and muscle dysfunctions to market. Despite a reduction in the number of scientists following restructuring, stable demand for orphan drugs renders the firm's development independent of economic cycles and inflationary processes.

To build a high-quality portfolio, I utilize total assets (equity + liabilities), reverse-engineered via ROA to assess the actual scale of the business, which allows for the elimination of market illusions through the analysis of aggregate resources; in the case of Reneo Pharmaceuticals (RPHM), this indicator reflects the value of the proprietary patent base amid post-trial restructuring, transforming the dynamics of assets (equity + liabilities) into a survival marker for the biotech firm.